Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2026

Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Overview

• The Cytogam (Cytomegalovirus Immune Globulin Intravenous) market growth in the historic period has been driven by high cmv risk in transplant recipients, established use of immune globulins • Market expansion is supported by growth in transplant volumes, increasing immunosuppressed populations • Growth Driver: Growth In Transplant Procedures Driving The Demand For Cytogam (Cytomegalovirus Immune Globulin Intravenous) In Organ Transplantation • Market Trend: Focus On Innovation And Regulatory Approvals To Gain Competitive Edge • North America was the largest region in 2025.

What Is Covered Under Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

Cytogam (Cytomegalovirus Immune Globulin Intravenous) is an intravenous medication used to prevent and treat Cytomegalovirus (CMV) infections in immunocompromised patients, such as organ transplant recipients. It contains antibodies derived from human plasma, which help fight the CMV virus. It is typically administered to prevent CMV reactivation or infection. The treatment is often used in combination with antiviral therapies. It helps reduce the risk of CMV-related complications in vulnerable patients. The main dosage forms of cytogam (cytomegalovirus immune globulin intravenous) are intravenous (IV) injection and other forms (if applicable). Intravenous (IV) injection is a method of administering Cytogam (cytomegalovirus immune globulin intravenous) directly into the bloodstream through a vein. The clinical indication are prevention of cytomegalovirus (CMV) disease in transplant recipients, prophylaxis in solid organ transplant patients, prophylaxis in hematopoietic stem cell transplant patients, use in pregnant women with primary CMV infection. The patient population includes adult patients and pediatric patients, and the distribution channel includes hospital pharmacies, outpatient clinics, and specialty pharmacies.

What Is The Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Growth Forecast?

The growth in the forecast period can be attributed to growth in transplant volumes, increasing immunosuppressed populations, expansion of antiviral combination therapies, improved cmv screening, rising specialty pharmacy access. Major trends in the forecast period include rising use in transplant patients, increased demand for cmv prophylaxis, combination therapy with antivirals, hospital based immunoglobulin administration, focus on immunocompromised populations.

Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Segmentation

1) By Dosage Form: Intravenous (IV) Injection, Other Forms (if applicable) 2) By Patient Population: Adult Patients, Pediatric Patients 3) By Distribution Channel: Hospital Pharmacies, Outpatient Clinics, Specialty Pharmacies

What Are The Drivers Of The Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

The rise in the number of transplant procedures is expected to propel the growth of the cytogam (cytomegalovirus immune globulin intravenous) market going forward. Transplant procedures refer to medical surgeries where an organ or tissue is transferred from one person (donor) to another (recipient) to replace a damaged or non-functioning organ. The rise in the number of transplant procedures can be attributed to several key factors such as an increase in organ donations, advancements in medical technology, and improved treatment options. Cytogam (cytomegalovirus immune globulin intravenous) is primarily used to prevent or treat cytomegalovirus (CMV) infections in immunocompromised patients, especially those undergoing organ transplants. For instance, in January 2024, according to OPTN (Organ Procurement and Transplantation Network), a US-based government department, there were 46,632 organ transplants performed by both living and deceased donors in 2023. This represents an 8.7% increase over 2022. Therefore, the rise in the number of transplant procedures is driving the growth of the cytogam cytomegalovirus immune globulin intravenous) market. The rising chronic disease is expected to propel the growth of the cytogam (cytomegalovirus immune globulin intravenous) market going forward. A chronic disease is a long-lasting health condition that progresses slowly and usually persists for years. Chronic diseases are increasing mainly due to unhealthy lifestyle habits such as poor diet and physical inactivity. Cytogam (cytomegalovirus immune globulin intravenous) is used in chronic disease care by strengthening immune defense against CMV infections in high-risk patients, especially those with long-term immunocompromised conditions. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the rising chronic disease will drive the growth of the cytogam (cytomegalovirus immune globulin intravenous) industry.

Key Players In The Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market

Major companies operating in the cytogam (cytomegalovirus immune globulin intravenous) market are CSL Behring

Global Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Trends and Insights

Major companies operating in the cytogam (cytomegalovirus immune globulin intravenous) market are focusing on innovative approaches, such as manufacturing technology transfer to gain a competitive edge. Manufacturing technology transfer refers to the process of transferring the knowledge, processes, and techniques required to produce a product from one site or company to another, ensuring the new facility can manufacture the product with the same quality and standards as the original. For instance, in May 2023, Kamada Ltd., an Israel-based biopharmaceutical company, launched commercial sale of CYTOGAM in the US, following FDA approval of the technology transfer from CSL Behring. This product, indicated for the prevention of CMV disease in transplant patients, is the only FDA-approved IgG product for this purpose. Kamada's manufacturing facility in Beit Kama, Israel, now produces CYTOGAM, with availability in Canada expected later this year.

Regional Insights

North America was the largest region in the cytogam (cytomegalovirus immune globulin intravenous) market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market?

The cytogam (cytomegalovirus immune globulin intravenous) market consists of sales of Cytogam (Cytomegalovirus Immune Globulin Intravenous) 500 mg/10 mL and Cytogam (Cytomegalovirus Immune Globulin Intravenous) 1000 mg/20 mL. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2026?

The cytogam (cytomegalovirus immune globulin intravenous) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cytogam (cytomegalovirus immune globulin intravenous) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.